Background Patients with moderate-to-severe allergic rhinitis who are inadequately controlled despite treatment according to current rhinitis management guidelines have a significant unmet medical need. Such patients have a negative impact on daily functioning and are at risk of developing serious comorbidities, such as asthma and chronic rhinosinusitis. Objective To assess the efficacy and safety of omalizumab in poorly controlled allergic rhinitis under a meta-analysis framework. Methods MEDLINE and the Cochrane Central Register of Controlled Trials were searched through September 2013. Studies on the efficacy of omalizumab in allergic rhinitis that assessed clinical outcomes were selected. Descriptive and quantitative information was extracted; mean differences and relative risk estimates were synthesized under a fixed or random effects model. Heterogeneity was assessed by using the Q statistic and the I2 metric. Subgroup analyses were performed for the presence of specific immunotherapy treatment. Results Of the 352 citations retrieved, 11 studies of 2870 patients were finally included. A statistically significant reduction in the daily nasal symptom severity score (standardized mean difference −0.67 [95% CI, −1.3 to −0.31]; P < .0001; I2, 92%) and a statistically significant reduction in daily nasal rescue medication score (−0.22 [95% CI, −0.39 to −0.05; P = .01; I2, 58%) were observed. There was not a statistically significant difference in the occurrence of any adverse event (relative risk 1.06 [95% CI, 0.94-1.19; I2, 55%). Conclusions Omalizumab is statistically significantly associated with symptom relief, decreased rescue medication use, and improvement of quality of life in patients with inadequately controlled allergic rhinosinusitis.